670 related articles for article (PubMed ID: 29997889)
1. Risk factors for hospitalized patients with resistant or multidrug-resistant
Raman G; Avendano EE; Chan J; Merchant S; Puzniak L
Antimicrob Resist Infect Control; 2018; 7():79. PubMed ID: 29997889
[TBL] [Abstract][Full Text] [Related]
2. Assessing Rates of Co-Resistance and Patient Outcomes in Multidrug-Resistant Pseudomonas aeruginosa.
Appaneal HJ; Caffrey AR; Lopes V; Piehl EC; Puzniak LA; LaPlante KL
Microbiol Spectr; 2022 Oct; 10(5):e0233622. PubMed ID: 36005836
[TBL] [Abstract][Full Text] [Related]
3. A Combination Antibiogram Evaluation for
Puzniak L; DePestel DD; Srinivasan A; Ye G; Murray J; Merchant S; DeRyke CA; Gupta V
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917987
[No Abstract] [Full Text] [Related]
4. Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis.
Ponce de Leon A; Merchant S; Raman G; Avendano E; Chan J; Tepichin Hernandez G; Sarpong E
BMC Infect Dis; 2020 Mar; 20(1):250. PubMed ID: 32220233
[TBL] [Abstract][Full Text] [Related]
5. Impact of a multimodal strategy combining a new standard of care and restriction of carbapenems, fluoroquinolones and cephalosporins on antibiotic consumption and resistance of Pseudomonas aeruginosa in a French intensive care unit.
Abbara S; Pitsch A; Jochmans S; Hodjat K; Cherrier P; Monchi M; Vinsonneau C; Diamantis S
Int J Antimicrob Agents; 2019 Apr; 53(4):416-422. PubMed ID: 30537533
[TBL] [Abstract][Full Text] [Related]
6. Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients.
Martínez JA; Delgado E; Martí S; Marco F; Vila J; Mensa J; Torres A; Codina C; Trilla A; Soriano A; Alquezar A; Castro P; Nicolás JM
Intensive Care Med; 2009 Mar; 35(3):439-47. PubMed ID: 18936910
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
8. [Nosocomial infections caused by multiresistant Pseudomonas aeruginosa (carbapenems included): predictive and prognostic factors. A prospective study (2016-2017))].
Hernández A; Yagüe G; García Vázquez E; Simón M; Moreno Parrado L; Canteras M; Gómez J
Rev Esp Quimioter; 2018 Apr; 31(2):123-130. PubMed ID: 29564870
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal Microbiota Disruption and Risk of Colonization With Carbapenem-resistant Pseudomonas aeruginosa in Intensive Care Unit Patients.
Pettigrew MM; Gent JF; Kong Y; Halpin AL; Pineles L; Harris AD; Johnson JK
Clin Infect Dis; 2019 Aug; 69(4):604-613. PubMed ID: 30383203
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure.
Cobos-Trigueros N; Solé M; Castro P; Torres JL; Hernández C; Rinaudo M; Fernández S; Soriano Á; Nicolás JM; Mensa J; Vila J; Martínez JA
Crit Care; 2015 May; 19(1):218. PubMed ID: 25936721
[TBL] [Abstract][Full Text] [Related]
11. Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors.
Trinh TD; Zasowski EJ; Claeys KC; Lagnf AM; Kidambi S; Davis SL; Rybak MJ
Diagn Microbiol Infect Dis; 2017 Sep; 89(1):61-66. PubMed ID: 28716451
[TBL] [Abstract][Full Text] [Related]
12. Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit.
Kohlenberg A; Weitzel-Kage D; van der Linden P; Sohr D; Vögeler S; Kola A; Halle E; Rüden H; Weist K
J Hosp Infect; 2010 Apr; 74(4):350-7. PubMed ID: 20170982
[TBL] [Abstract][Full Text] [Related]
13. Risk of acquiring multidrug-resistant Gram-negative bacilli from prior room occupants in the intensive care unit.
Nseir S; Blazejewski C; Lubret R; Wallet F; Courcol R; Durocher A
Clin Microbiol Infect; 2011 Aug; 17(8):1201-8. PubMed ID: 21054665
[TBL] [Abstract][Full Text] [Related]
14. Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance.
Fernández-Barat L; Ferrer M; De Rosa F; Gabarrús A; Esperatti M; Terraneo S; Rinaudo M; Li Bassi G; Torres A
J Infect; 2017 Feb; 74(2):142-152. PubMed ID: 27865895
[TBL] [Abstract][Full Text] [Related]
15. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes.
Shanthi M; Sekar U
J Assoc Physicians India; 2009 Sep; 57():636, 638-40, 645. PubMed ID: 20214000
[TBL] [Abstract][Full Text] [Related]
16. In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
Ma W; Li J; Wang D; Yu C; Sun S
Lett Appl Microbiol; 2019 Sep; 69(3):198-203. PubMed ID: 31236975
[TBL] [Abstract][Full Text] [Related]
17. Antibiotics associated with acquisition of carbapenem-resistant Pseudomonas aeruginosa in ICUs: a multicentre nested case-case-control study.
Coppry M; Jeanne-Leroyer C; Noize P; Dumartin C; Boyer A; Bertrand X; Dubois V; Rogues AM
J Antimicrob Chemother; 2019 Feb; 74(2):503-510. PubMed ID: 30376042
[TBL] [Abstract][Full Text] [Related]
18. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.
Maraolo AE; Cascella M; Corcione S; Cuomo A; Nappa S; Borgia G; De Rosa FG; Gentile I
Expert Rev Anti Infect Ther; 2017 Sep; 15(9):861-871. PubMed ID: 28803496
[TBL] [Abstract][Full Text] [Related]
19. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
Lodise TP; Miller CD; Graves J; Furuno JP; McGregor JC; Lomaestro B; Graffunder E; McNutt LA
Antimicrob Agents Chemother; 2007 Feb; 51(2):417-22. PubMed ID: 17158943
[TBL] [Abstract][Full Text] [Related]
20. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
